Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR6 | P46095 | 8/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.36 |
| ▸ | RORC | P51449 | 2/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17770082 | 0.91 | GPR6 (0.36) | GPR6USP30PANK3CNR2MAP3K12 | |
| SCHEMBL17770084 | 0.91 | GPR6 (0.36) | GPR6USP30PANK3CNR2MAP3K12 | |
| SCHEMBL19736307 | 0.89 | RPS6KA3 (0.42) | CNR2MAP3K12 | |
| SCHEMBL19736506 | 0.89 | FDPS (0.40) | CNR2 | |
| SCHEMBL22239707 | 0.88 | CNR2 (0.35) | CNR2 | |
| SCHEMBL19736162 | 0.88 | CNR2 (0.35) | CNR2 | |
| SCHEMBL19736429 | 0.88 | FGFR1 (0.39) | MAP3K12 | |
| SCHEMBL19736279 | 0.87 | TYK2 (0.38) | HRH3CNR2 | |
| SCHEMBL22239575 | 0.87 | MAP3K12 (0.36) | CNR2MAP3K12 | |
| SCHEMBL19736179 | 0.87 | HRH3 (0.37) | HRH3CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362234-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GPR6 2859/4885USP30 198/4885HRH3 3117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.